Analysis of Ministry of Health’s Handling of OIA Request #29775 – Genetic Content and Half-Life of Comirnaty

Summary: This OIA request (April 14, 2024) sought specific data on the presence of dsDNA/ssDNA in the Pfizer Comirnaty vaccine, the half-life of its synthetic mRNA, and the half-life of the spike protein produced. As of July 17, 2025, the Ministry of Health has not provided a substantive response, exceeding the 20-working-day deadline mandated by the Official Information Act 1982. This analysis identifies tactics of delay, obfuscation, and misdirection, drawing on patterns observed in related OIA requests on fyi.org.nz.

Key Findings:

Delay: The Ministry acknowledged the request (H2024047111) but failed to respond by May 14, 2024, or notify of an extension, violating OIA requirements. Similar delays are evident in requests #17904 and #16521, suggesting systemic issues with vaccine-related transparency.

Obfuscation: By not addressing the specific questions about genetic content and half-life, the Ministry avoids disclosing potentially sensitive data. Related requests (#23680, #15909) show a pattern of withholding detailed composition or safety data, often citing confidentiality or privacy.

Misdirection: The acknowledgment’s generic links to Ministry websites (e.g., https://covid19.govt.nz/) are irrelevant to the technical questions asked, a tactic seen in requests #16521 and #16760 to deflect requesters to curated information.

Potential Disinformation by Omission: The lack of response prevents public access to data on DNA content and half-life, critical for assessing vaccine safety. Request #16034 shows the Ministry contradicting international data (e.g., Japanese PMDA reports) without evidence, raising concerns about misleading omissions.

Guidance for Researchers:

Escalate Non-Responses: If the Ministry fails to respond, lodge a complaint with the Ombudsman (contact: [email protected], 0800 802 602) to enforce OIA compliance.

Request Specific Data: Frame questions precisely (e.g., quantify dsDNA/ssDNA in nanograms per dose) to reduce room for vague responses. Cross-reference with international studies, such as Japan’s PMDA report.

Highlight Public Interest: Emphasize the public health importance of transparency in vaccine composition and pharmacokinetics, as seen in request #23680, to counter confidentiality excuses.

Compare with Other Agencies: Note how other agencies (e.g., Auckland Council in #13414) clearly admit when data is unavailable, pressing the Ministry to do the same.

Use Related Requests: Review requests #16106 (successful for genotoxicity data), #26670 (DNA content), and #16034 (pharmacokinetics) to build a case for demanding similar data.

Conclusion: The Ministry’s non-response to this request mirrors a broader pattern of delaying or withholding vaccine-related information, undermining public trust. Researchers should persist with follow-ups, use the Ombudsman, and collaborate on fyi.org.nz to share findings and strategies. Transparency in vaccine safety data is critical for informed consent and public health.

Additional Notes for Your Work

Critical Examination of Narrative: The Ministry’s consistent delays and vague responses across vaccine-related OIAs suggest a reluctance to engage with technical questions that could challenge the safety narrative of Comirnaty. The contradiction in request #16034 (denying ovarian bioaccumulation despite Japanese data) underscores the need to verify Ministry claims against primary sources like Pfizer’s studies or international regulators.

Supporting Resources: Use the Japanese PMDA report () and successful request #16106 () as benchmarks for what data the Ministry may hold but is not releasing.

Final Conclusion

The Ministry of Health’s handling of OIA request #29775 exhibits clear delay and potential obfuscation through non-response, with misdirection implied by the provision of irrelevant links. While no direct misinformation or disinformation is present due to the lack of a substantive reply, the silence itself may constitute omission of critical public health data. Deep research across fyi.org.nz reveals a pattern of similar tactics in other Comirnaty-related requests, reinforcing the need for persistent follow-up and escalation.

Great analysis. Keep the foot on the pedal

Watching with curiousity

From Innovation to Inquiry — COVID -19 mRNA
Vaccination and Its Global Consequences —
with Special Reference to New Zealand
Bruce Rapley, PhD
Consultant and Independent Researcher, Smart Technology, New Zealand;

Abstract
The COVID-19 pandemic involved the rapid deployment of novel biomedical technologies. Chief
among them were synthetic RNAs, introduced with limited longitudinal data, yet supported by
institutional consensus, and expedited regulatory pathways. Subsequent developments revealed
questions regarding safety, ethics, efficacy, and governance. This formal review, with specific
reference to New Zealand, examines the COVID-19 response, using synthetic RNA distributed
under Emergency Use Authorizations. A range of post-deployment signals, including immunological
anomalies (IgG4 class switching), clotting disorders, and residual DNA elements, remain
insufficiently investigated. Regulatory responses have not met the standard of precaution typically
applied to novel gene therapies. At the same time, low-cost interventions such as ivermectin were de-
prioritized, or suppressed. The temporal association between vaccine rollouts and excess non-
COVID mortality in several high-uptake nations warrants systematic, transparent analysis. To date,
no national authority has published comprehensive disaggregated mortality data by vaccination
status.
Keywords: adverse events, COVID-19 vaccination, Emergency Use Authorization, EUA, genetic engineering, IgG4 class
switching, mRNA vaccination, plasmid DNA, post-market surveillance, therapeutic suppression, ivermectin, spike protein toxicity,
regulatory oversight failure, scientific censorship, turbo cancer, vaccine-induced thrombotic thrombocytopenia, VITT

https://ijvtpr.com/index.php/IJVTPR/arti...